Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

22 May 2015 National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

The National Hemophilia Foundation (NHF) has awarded CSL Behring its 2015 Corporate Leadership Award as recognition for the company’s longstanding and unwavering commitment to advancing science and improving the care of the bleeding disorders community. The award was accepted by Paul Perreault, CEO and Managing Director, CSL Limited, during the NHF Annual Spring Soiree in New York City on May 21.

> Read More
14 May 2015 SCIENCE, INFORMATION, AND TECHNOLOGY DRIVING EVOLUTION OF GLOBAL HEALTHCARE

Scientific advancements, more readily available medical information and emerging technologies are driving greater patient engagement, improving diagnosis and treatment, and enabling people with life-threatening diseases to live longer and healthier lives, said CSL Limited CEO and Managing Director Paul Perreault. CSL is the parent company of CSL Behring.

> Read More
23 April 2015 CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSL Behring announced today that the company has named five recipients of the 2015 CSL Behring Professor Heimburger Award for coagulation research. Now in its eighth year, the global awards program helps fund the work of young, emerging researchers by providing start-up grants. The goal of the award is to encourage the next generation of coagulation specialists to establish themselves professionally and to continue innovative research. The total value of the five grants is 100,000 euros.

> Read More
14 April 2015 CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia

In recognition of World Hemophilia Day April 17, the World Federation of Hemophilia (WFH) and CSL Behring announced today that CSL Behring has once again committed to donating bleeding disorder protein therapy international units (IUs) to the WFH Global Alliance for Progress (GAP) Program and other WFH programs, as well as making significant financial contributions to WFH.

> Read More
30 March 2015 European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients

CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Upon European Commission approval, rIX-FP will provide hemophilia B patients in the European Union (EU), as well as the European Economic Area (EEA) countries, with a long-acting treatment option with dosing intervals up to 14 days.

> Read More
Page 1 of 6 Next | Last

Share
LinkedIn Twitter Facebook Google+